Effect of silymarin on biochemical indicators in patients with liver disease: Systematic review with meta-analysis

Preventive use of a hepatoprotectant against anti-tuberculosis drug-induced liver injury: A randomized controlled trial

(2016) Simin Zhang et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

A double-blinded randomized controlled trial of silymarin for the prevention of antituberculosis drug-induced liver injury

(2015) Chote Luangchosiri et al.   BMC Complementary and Alternative Medicine

Efficacy of Lifestyle Changes in Subjects with Non-Alcoholic Liver Steatosis and Metabolic Syndrome May Be Improved with an Antioxidant Nutraceutical: A Controlled Clinical Study

(2015) Gianpaolo Sorrentino et al.   Drugs in research & development

Effects of Mediterranean diet supplemented with silybin–vitamin E–phospholipid complex in overweight patients with non-alcoholic fatty liver disease

(2015) Ludovico Abenavoli et al.   Expert Review of Gastroenterology & Hepatology

Serum Oxidative Stress Markers and Lipidomic Profile to Detect NASH Patients Responsive to an Antioxidant Treatment: A Pilot Study

(2014) Paola Stiuso et al.   Oxidative Medicine and Cellular Longevity

Chemopreventive and Anti-Cancer Efficacy of Silibinin Against Growth and Progression of Lung Cancer

(2013) Samiha Mateen et al.   NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL

Spirulina platensis versus silymarin in the treatment of chronic hepatitis C virus infection. A pilot randomized, comparative clinical trial

(2012) Mostafa Yakoot et al.   BMC GASTROENTEROLOGY

Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: A randomized controlled trial

(2012) Carmela Loguercio et al.   FREE RADICAL BIOLOGY AND MEDICINE

Effects of Metformin, Pioglitazone, and Silymarin Treatment on Non- Alcoholic Fatty Liver Disease: A Randomized Controlled Pilot Study

(2012) Ali Akbar Hajiaghamohammadi et al.   Hepatitis Monthly

Effect of Silymarin (Milk Thistle) on Liver Disease in Patients With Chronic Hepatitis C Unsuccessfully Treated With Interferon Therapy

(2012) Michael W. Fried   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Silibinin modulates lipid homeostasis and inhibits nuclear factor kappa B activation in experimental nonalcoholic steatohepatitis

(2012) Federico Salamone et al.   Translational Research

Role of silymarin to treat fibrosis development in non-alcoholic fatty liver disease

(2011) Ludovico Abenavoli   HEPATOLOGY RESEARCH

Silymarin use and liver disease progression in the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis trial

(2010) N. D. Freedman et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Milk thistle in liver diseases: past, present, future

(2010) Ludovico Abenavoli et al.   PHYTOTHERAPY RESEARCH

Silymarin, the antioxidant component and Silybum marianum extracts prevent liver damage

(2009) E. Shaker et al.   FOOD AND CHEMICAL TOXICOLOGY

A randomized controlled trial to assess the safety and efficacy of silymarin on symptoms, signs and biomarkers of acute hepatitis

(2009) Samer S. El-Kamary et al.   PHYTOMEDICINE

Multitargeted therapy of cancer by silymarin

(2008) Kumaraguruparan Ramasamy et al.   CANCER LETTERS

The Pharmacokinetics of Silymarin Is Altered in Patients with Hepatitis C Virus and Nonalcoholic Fatty Liver Disease and Correlates with Plasma Caspase-3/7 Activity

(2008) S. J. Schrieber et al.   DRUG METABOLISM AND DISPOSITION

Silybin Treatment is Associated With Reduction in Serum Ferritin in Patients With Chronic Hepatitis C

(2008) Julie M. Bares et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

An Updated Systematic Review with Meta-Analysis for the Clinical Evidence of Silymarin

(2008) R. Saller et al.   FORSCHENDE KOMPLEMENTARMEDIZIN